Can Losartan Raise Blood Sugar Levels?

Losartan does not raise blood sugar in the vast majority of people who take it. The drug is widely considered “metabolically neutral,” and the largest clinical trial to test it head-to-head against another blood pressure medication found that losartan actually reduced the risk of developing new-onset diabetes. The picture gets more complicated in a few specific situations, though, and some people on losartan do see blood sugar changes they were not expecting.

What the Largest Clinical Trials Show

The most robust evidence on losartan and blood sugar comes from the LIFE trial, which enrolled more than 9,000 people with high blood pressure and signs of heart thickening. Patients randomized to losartan developed new-onset diabetes at a rate roughly 25 percent lower than those taking atenolol, a common beta-blocker. The difference was clear and statistically convincing: about 13 new cases per 1,000 patient-years with losartan versus about 17.5 with atenolol.¹ That trial lasted several years, which matters because blood sugar problems from a medication sometimes take time to emerge.

A separate study using euglycemic clamp testing, the gold-standard method for measuring how well the body handles insulin, found that losartan had no measurable effect on insulin sensitivity, glucose oxidation, or lipid profiles after 12 weeks of treatment. The researchers concluded that losartan is metabolically neutral, with no significant adverse effect on glucose or lipid metabolism.² That finding is reassuring: even under close measurement, losartan did not push fasting blood sugar or insulin resistance in the wrong direction.

One Small Study That Raised a Flag

Not every finding has been positive. A preliminary study in non-diabetic patients on chronic hemodialysis found that short-term losartan treatment increased fasting blood glucose from about 76 to 89 mg/dL. Insulin levels did not change, but the researchers calculated that pancreatic beta-cell function dropped by roughly half. They concluded that losartan may have a harmful effect on glucose balance in this particular group, mediated by reduced beta-cell output.³

The study was small, short, and limited to people whose kidneys had already failed, a group whose metabolic machinery works very differently from the general population. Hemodialysis itself disrupts hormone clearance, electrolyte balance, and insulin handling in ways that can amplify or distort drug effects. The result is worth knowing about, especially for nephrologists managing these patients, but it does not mean losartan raises blood sugar in people with functioning kidneys. No large-scale trial in the broader hypertensive population has replicated this finding.

How Losartan Affects Blood Sugar at the Cellular Level

Losartan works by blocking the angiotensin II type 1 receptor (AT1R). That receptor is best known for its role in raising blood pressure, but it also shows up in places that matter for blood sugar, including the pancreas and skeletal muscle. Blocking it sets off a chain of effects that, on the whole, tilt toward improving rather than worsening glucose metabolism.

In the pancreas, angiotensin II acts as a brake on insulin release. It reduces blood flow to the islets (the clusters of cells that produce insulin) and suppresses the production of insulin itself. When losartan blocks that signal, the brake lifts. Animal studies using a well-established mouse model of type 2 diabetes showed that losartan improved glucose-stimulated insulin release, delayed the onset of diabetes, and reduced hyperglycemia.⁴ Lab work on human islets confirmed part of this story: losartan protected insulin-producing cells from damage caused by high glucose exposure and preserved their ability to secrete insulin.⁵

Losartan also has an unusual trick that sets it apart from some other drugs in its class. When the liver processes losartan, it produces a metabolite called EXP3179 that activates a receptor called PPARγ, the same target that the diabetes drug pioglitazone works on. EXP3179 reaches about half the maximum PPARγ activation that pioglitazone achieves, making it a partial activator. This may contribute to some of the favorable metabolic effects seen in clinical trials.⁶ Worth noting, though: while losartan binds to PPARγ in test-tube experiments, the amount of activation it produces inside living cells is modest compared to telmisartan, a related drug that acts as a much stronger PPARγ activator.⁷

How Losartan Stacks Up Against Other Blood Pressure Drugs

Blood pressure medications are not all equal when it comes to blood sugar. Some make things noticeably worse (older beta-blockers and thiazide diuretics at high doses), some are neutral, and some may offer a mild benefit. Where losartan lands depends on what you compare it to.

Against beta-blockers like atenolol, losartan looks good. The LIFE trial data described earlier showed a meaningful reduction in new-onset diabetes with losartan. That advantage likely comes partly from losartan’s neutral-to-positive metabolic profile and partly from the fact that beta-blockers can slow metabolism, promote weight gain, and blunt insulin secretion.

Against ACE inhibitors, losartan performs respectably but may not be quite as beneficial. A meta-analysis pooling data from randomized controlled trials found no meaningful difference in fasting glucose or fasting insulin between the two drug classes overall. However, when the analysis looked at longer treatment periods (beyond 12 weeks) or specifically at patients who already had diabetes, ACE inhibitors showed a slight edge in insulin sensitivity.⁸ A head-to-head trial comparing losartan to lisinopril (an ACE inhibitor) found the same pattern: lisinopril improved insulin sensitivity by a clamp-measured metric, while losartan did not change it significantly in either direction.⁹ The practical difference is small for most people, but if your doctor is choosing between these two classes and blood sugar is a major concern, ACE inhibitors may have a marginal advantage.

Against telmisartan, another drug in the same class as losartan (both are angiotensin receptor blockers), the contrast is sharper. A trial in hypertensive patients with metabolic syndrome found that telmisartan significantly lowered fasting glucose, fasting insulin, insulin resistance scores, and HbA1c, while losartan did not change any of those measures.¹⁰ Telmisartan’s stronger PPARγ activity likely explains the difference. This does not mean losartan is bad for blood sugar; it just means that “metabolically neutral” and “metabolically beneficial” are not the same thing, and losartan tends to fall in the neutral camp.

When the Combination Pill Is the Real Problem

Here is where things get practically important. Losartan is frequently prescribed in combination with hydrochlorothiazide (HCTZ), a thiazide diuretic. The combined pill is sold under brand names like Hyzaar and various generics. If you are taking one of these combination products and your blood sugar has crept up, the most likely culprit is the HCTZ component, not the losartan.

A study comparing the metabolic effects of adding either HCTZ or amlodipine (a calcium channel blocker) to losartan in patients with type 2 diabetes found that HbA1c increased in the group receiving HCTZ but not in the group receiving amlodipine.¹¹ That is a meaningful distinction because the patient often attributes the blood sugar change to “my losartan” without realizing a second drug is in the pill.

The mechanism behind the thiazide effect is well established. Thiazide diuretics can lower potassium levels, and that potassium loss impairs the pancreas’s ability to release insulin in response to glucose. Classic research demonstrated that when potassium losses were prevented during thiazide treatment, no changes in glucose tolerance occurred at all. Only when hypokalemia (low potassium) was allowed to develop did glucose handling worsen.¹² If you are on a losartan/HCTZ combination and your blood sugar is rising, talk to your doctor about checking your potassium level and whether an alternative add-on medication might be better for you.

Losartan itself tends to raise potassium slightly, as all drugs blocking the renin-angiotensin system do, which is part of why the combination with a potassium-wasting diuretic seems balanced on paper. But the balance does not always hold perfectly, and individuals respond differently.

If You Also Take Diabetes Medications

People with type 2 diabetes often take losartan alongside glucose-lowering drugs, and here the interaction cuts the other direction: losartan may push blood sugar lower, not higher. Animal research found that losartan enhanced the blood-sugar-lowering effect of a glimepiride-plus-metformin combination by more than 40 percent in both single-dose and multi-dose experiments.¹³ That degree of enhancement is large enough to matter clinically. Translating directly from animal studies to humans requires caution, but the finding is consistent with case reports of unexpected hypoglycemia in people starting losartan while on sulfonylureas or insulin.

If you have diabetes and are starting losartan, it is worth monitoring your blood sugar more frequently during the first few weeks, especially if you take a sulfonylurea (glimepiride, glipizide, glyburide) or insulin. The risk here is not that losartan will raise your blood sugar but that it might lower it enough to cause symptoms like shakiness, sweating, or confusion. Your doctor may need to adjust your diabetes medication dose downward.

Losartan’s Kidney Benefits and Why They Matter for Blood Sugar

Losartan is one of the few blood pressure drugs proven to slow kidney damage in people with type 2 diabetes. The RENAAL trial showed that losartan reduced the risk of kidney failure by about 28 percent and cut the rate of protein spilling into the urine by 35 percent over roughly three and a half years.¹⁴ Kidney protection is relevant to blood sugar because declining kidney function disrupts insulin clearance, alters glucose handling, and often makes diabetes harder to manage. Preserving kidney function indirectly helps stabilize blood sugar over the long term.

This is a roundabout benefit, not a direct glucose-lowering effect, but it matters when patients and doctors weigh the full metabolic picture. A drug that is neutral on blood sugar in the short run but protects the kidneys for years may end up producing better glucose control overall than a drug with a modest short-term metabolic benefit and no kidney protection.

Genetic Variation in How Your Body Processes Losartan

Most of losartan’s active work is done by its metabolites, and the liver enzyme CYP2C9 is responsible for producing them. People carry different versions of the CYP2C9 gene, and those differences affect how efficiently the drug is converted to its active forms. A study in patients with kidney disease found that people with certain CYP2C9 variants had significantly different blood pressure responses to losartan compared to those with the standard gene version, particularly in patients whose kidney problems stemmed from diabetes or hypertension.¹⁵

The metabolic implications are still being studied, but the logic is straightforward: if your body produces less of losartan’s active metabolites (including the one that activates PPARγ), you may get less of whatever modest metabolic benefit the drug provides. This could partly explain why some individuals seem to experience no glucose-related benefit from losartan while others in the same trial do. Pharmacogenomic testing for CYP2C9 is available but rarely ordered in routine practice. It tends to come up more when a patient is not responding to standard doses of losartan for blood pressure control, rather than for blood sugar concerns specifically.

Who Should Actually Worry

For the vast majority of people prescribed losartan, blood sugar is not something the drug is going to push in the wrong direction. The populations that should pay closer attention are narrow:

Hemodialysis patients: The small study showing a fasting glucose increase and reduced beta-cell function applied specifically to people on chronic hemodialysis. If you are in this group, your nephrologist should be tracking blood sugar regardless of which blood pressure drug you take.
People on losartan/HCTZ combinations: If your blood sugar has risen since starting a combination pill, the thiazide component is the likely cause. Ask your doctor whether switching to losartan alone or pairing it with a different add-on drug would help.
People on sulfonylureas or insulin: The interaction goes the other direction. Losartan may amplify the glucose-lowering effect of these medications, raising the risk of hypoglycemia rather than hyperglycemia.

Everyone else taking losartan for high blood pressure can reasonably expect the drug to leave their blood sugar alone. If anything, the weight of evidence leans slightly in the favorable direction, though not enough to consider losartan a treatment for blood sugar problems on its own. Routine monitoring that your doctor already performs during blood pressure management, typically including periodic basic metabolic panels, will catch any unexpected changes.